查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2056571

人類微生物組市場規模、佔有率、趨勢和預測：按產品類型、應用、疾病和地區分類，2026-2034 年

Human Microbiome Market Size, Share, Trends and Forecast by Product, Application, Disease Type, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年全球人類微生物組市場規模為11.163億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以15.17%的複合年成長率成長，到2034年達到41.279億美元。目前，北美市場佔據主導地位，預計2025年將佔43.5%的市場。醫療保健系統正從治療主導模式轉變為預防主導模式。此外，定序技術和生物資訊學平台的持續發展也為市場帶來了良好的前景。同時，人們對腸道健康與整體健康之間關聯的認知不斷加深，也促進了人類微生物組市場佔有率的擴大。

隨著研究揭示人類微生物組在醫療保健、營養和生物技術領域的新應用，該市場正迅速成長。製藥和生技公司正加大投資，探索以微生物組為基礎的療法在慢性病、胃腸道疾病和代謝性疾病方面的潛力。這些公司正在推出創新的診斷產品和個人化醫療解決方案，重點關注微生物組在整體健康中的作用。隨著消費者對益生菌、益生元和機能性食品的認知度不斷提高，市場也不斷擴張。營養強化食品和補充品越來越受到關注，因為製造商正著力研發以微生物組為導向的產品。同時，定序和生物資訊技術的進步使得對微生物組數據進行詳細分析成為可能，加速了藥物發現和臨床開發。

隨著研究機構、生物技術公司和製藥業對基於微生物組的創新表現出日益濃厚的興趣，美國人類微生物組市場正在穩步擴張。隨著微生物組的臨床意義日益受到重視，在胃腸道疾病、自體免疫疾病和代謝性疾病等領域，基於微生物組的治療方法需求不斷成長。各公司正在開發新一代益生菌、益生元和合合益素，並投資於針對個人微生物組特徵的個人化營養和精準醫療策略。政府機構和私人投資者透過資助微生物組研究、加速臨床試驗和產品開發，推動了該市場的發展。改進的定序工具和生物資訊學平台使科學家能夠更詳細地分析複雜的微生物群落。這些技術進步正在加強藥物研發流程和診斷解決方案。史丹佛大學醫學院的研究人員及其團隊對86名受試者的腸道、口腔、鼻腔和皮膚中的細菌進行了長達六年的追蹤研究，以揭示健康微生物組的定義因素。這項研究也揭示了微生物組與健康之間的多種關係。例如，研究表明，2 型糖尿病患者的微生物組穩定性較低，多樣性也較低。

人類微生物組市場的發展趨勢：

人們越來越關注預防醫學和個人化醫療

隨著醫療保健系統從治療主導轉向預防主導模式，人類微生物組產業正在蓬勃發展。消費者和患者越來越尋求能夠改善長期健康狀況並降低非傳染性疾病風險的解決方案。個人化醫療正發揮著至關重要的作用，基於微生物組的診斷和治療方法正被開發出來，以滿足個別微生物組譜的需求。各公司正在整合基因定序和生物資訊技術，以提供個人化干預措施來治療肥胖症、糖尿病、自體免疫疾病和胃腸道疾病等。這不僅正在革新消費者需求，也吸引了許多致力於開發精準醫療的製藥和生技公司進行巨額投資。隨著人們對微生物組在影響免疫、新陳代謝和心理健康方面作用的認知不斷提高，個人化醫療保健解決方案的採用正在加速推進。因此，對個人化預防策略的關注正在推動人類微生物組市場的成長。 2025年，印度首家綜合性腸道健康公司Sova Health在消化器官系統健康領域取得了突破性進展。該品牌以其客製化益生菌和個人化腸道平衡解決方案而聞名，現推出一系列診斷工具，旨在以前所未有的精準度和科學依據來解讀腸道健康。該公司表示，透過推出腸道微生物組測試 (GMT) 和食物不耐症測試 (FIT)，旨在幫助消費者了解自身症狀，並客製化相應的解決方案。

定序和生物資訊學的進展

在定序技術和生物資訊學平台持續進步的推動下，市場正快速成長。次世代定序（NGS）技術使科學家能夠以高精度、高速度和高效率研究微生物群落。生物資訊解決方案日趨完善，能夠分析大規模資料集，使科學家能夠更有效率地檢測微生物生物標記並研究宿主與微生物組之間的關係。這些進步使得人們能夠更深入地了解人類微生物組的複雜運作機制，從而發現新的治療方法、診斷方法和食品。因此，人類微生物組市場前景光明。製藥和生物技術產業正在採用這些技術來加速藥物研發和臨床試驗，大幅縮短研發週期。此外，先進的計算模型能夠進行預測性模擬，幫助科學家針對特定疾病設計個體化最佳化治療方法。隨著定序成本的降低和運算能力的提升，微生物組科學的普及程度不斷提高，進一步推動了創新和產業成長。因此，技術進步是支撐這一發展勢頭的關鍵驅動力。該出版商預測，到 2033 年，全球生物資訊學市場將達到 394 億美元。

消費者對機能性食品和營養補充品的需求日益成長

人類微生物組市場的一個關鍵趨勢是人們對腸道健康與整體健康之間關聯的認知不斷加深。消費者對免疫功能、消化功能以及預防慢性疾病的關注，促使他們將益生菌、益生元和機能性食品納入日常飲食中。食品飲料公司正透過推出注重微生物組的產品來推動創新，這些產品被定位為天然且經科學驗證的健康解決方案。這一趨勢也得益於人們對「個人化營養」需求的日益成長，個人化營養根據個人的微生物組特徵來制定飲食和補充劑方案。有關微生物組功能的資訊正透過社群媒體、健康宣傳活動和科學傳播，從而推動消費者行為的改變。零售通路和電子商務平台也透過提高微生物組相關產品的可及性來推動需求。隨著注重健康的消費者越來越傾向於預防醫學和自然療法而非藥物療法，機能性食品和補充劑產業對市場發展的影響力也不斷增強。 2024年，營養、健康和美容領域的領導者dsm-firmenich與益生菌專家Lallemand Health Solutions宣佈建立創新合作夥伴關係，推出一款突破性的合益素增效嬰幼兒營養產品。此創新方案將dsm-firmenich的人類乳寡糖（HMO）與Lallemand Health Solutions的益生菌結合，有望產生協同效應，促進嬰幼兒健康和生長發育。此方案旨在培育類似母乳哺育嬰兒的腸道菌群，進而增強免疫系統、改善腸道菌叢，並促進理想的發育進程。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球人類微生物組市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 益生菌
  • 益生元
  • 診斷測試
  • 製藥
  • 特殊醫學用途食品
  • 其他

第7章 市場區隔：依應用領域分類

  • 治療
  • 診斷

第8章 市場區隔：依疾病類型分類

  • 肥胖
  • 糖尿病
  • 自體免疫疾病
  • 癌症
  • 消化系統疾病
  • 中樞神經系統疾病
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • 4D pharma plc
    • Atlas Biomed Group Limited
    • BIOHM
    • BiomX
    • Bione
    • DayTwo Inc.
    • ENTEROME
    • Ferring BV
    • Finch Therapeutics
    • Second Genome Inc.
    • SynBioBeta LLC
    • Synthetic Biologics Inc.
    • Vedanta Biosciences Inc.
    • Viome Inc.
Product Code: SR112026A4420

The global human microbiome market size was valued at USD 1,116.3 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 4,127.9 Million by 2034, exhibiting a CAGR of 15.17% from 2026-2034. North America currently dominates the market, holding a market share of 43.5% in 2025. At present, healthcare system is moving away from treatment-driven models to prevention-driven models. Moreover, ongoing developments in sequencing technologies and bioinformatics platforms is offering a favorable market outlook. Apart from this, the increasing knowledge regarding the connection between the health of the gut and general well-being is expanding the human microbiome market share.

The market for the human microbiome is growing fast as studies are revealing new uses in healthcare, nutrition, and biotechnology. The industry is seeing increasing investments from pharmaceuticals and biotechnology firms that are investigating microbiome therapeutic opportunities in chronic diseases, gastrointestinal diseases, and metabolic disorders. Firms are releasing innovative diagnostic products and tailored medicine solutions that are focusing on the functioning of the microbiome in overall health. The market is growing as the awareness about probiotics, prebiotics, and functional foods is rising among the consumer base. Fortified foods and dietary supplements are attracting increasing attention with manufacturers highlighting microbiome-friendly products. Concurrently, technological developments in sequencing and bioinformatics are making it possible to delve deeper into microbiome data, which is facilitating drug discovery and clinical development.

The United States human microbiome market is increasing consistently since research centers, biotech companies, and pharmaceutical industries are enhancing their interest in microbiome-based innovations. The market is experiencing increasing demand for microbiome-based therapies in the form of gastrointestinal disorders, autoimmune disorders, and metabolic diseases because the clinical relevance of the microbiome is being increasingly acknowledged. Firms are creating next-generation probiotics, prebiotics, and synbiotics, investing in personalized nutrition and precision medicine strategies that are targeting personal microbiome profiles. Government agencies and private investors are funding microbiome research to expand, accelerating clinical trials and product development. Sequencing tools and bioinformatics platforms are improving, enabling scientists to better analyze intricate microbial communities. These technological advancements are consolidating drug discovery pipelines and diagnostic solutions. Researchers at Stanford Medicine and their team monitored the bacteria found in the gut, mouth, nose, and skin of 86 individuals for up to six years in an effort to understand what defines a healthy microbiome. The study also identified various connections between the microbiome and health, for example, people with Type 2 diabetes exhibited a limited stability and less diverse microbiome

Human Microbiome Market Trends:

Greater Emphasis on Preventive Health and Personalized Medicine

The human microbiome industry is growing as the healthcare system is moving away from treatment-driven models to prevention-driven models. Consumers and patients are becoming more inclined towards the solutions that are enabling long-term well-being and decreasing the risk of non-communicable diseases. Personalized medicine is taking a pivotal position, as diagnostics and therapeutics based on the microbiome are being created to address unique microbiome profiles. Firms are integrating genetic sequencing and bioinformatics technologies to provide personalized interventions that are treating ailments like obesity, diabetes, autoimmune diseases, and gastrointestinal disorders. Not only is this revolutionizing consumer demand, but it is also drawing huge investments from pharmaceutical and biotech companies looking to develop precision therapies. With growing consciousness about the role of the microbiome in influencing immunity, metabolism, and mental well-being, adoption of personalized healthcare solutions is gaining momentum. The emphasis on personalized prevention strategies is thus supporting the human microbiome market growth. In 2025, Sova Health, the first comprehensive gut health company in India, is making a transformative move in digestive health. Renowned for its tailored probiotics and individualized gut-balancing solutions, the brand is now launching a series of diagnostic tools intended to enhance gut health accuracy and scientific support like never before. By introducing its Gut Microbiome Test (GMT) and Food Intolerance Test (FIT), the company stated that it intends to assist consumers in understanding their symptoms and customizing solutions to address them.

Advances in Sequencing and Bioinformatics

The market is growing fast with ongoing developments in sequencing technologies and bioinformatics platforms. Next-generation sequencing (NGS) is facilitating scientists to investigate microbial communities with high precision, speed, and efficiency. Bioinformatics solutions are becoming more sophisticated to analyze large data sets so that scientists can detect microbial biomarkers and study host-microbiome relationships more efficiently. These advances are enabling the discovery of new therapeutics, diagnostics, and foods through better understanding of the intricate workings of the human microbiome, thereby offering a favorbale human microbiome market outlook. The pharmaceutical and biotech industries are embracing these technologies to fast-track drug development and clinical trials, which is lowering development times enormously. Further, enhanced computational models are enabling predictive simulations that are assisting scientists in designing tailored interventions against selected diseases. As the cost of sequencing is reducing and computing powers are increasing, access to microbiome science is rising, thus providing further stimulation for innovation and industry growth. Technological advancements are hence an important driver supporting momentum. The publisher predicts that the global bioinformatics market is projected to attain USD 39.4 Billion by 2033.

Increasing Consumer Demand for Functional Foods and Supplements

One of the major human microbiome market trends includes the riding the wave of increasing knowledge regarding the connection between the health of the gut and general well-being. Consumers are taking up probiotics, prebiotics, and functional foods as part of their diet by the day due to worries over immunity, digestion, and prevention of chronic diseases. Food and beverage players are turning innovative by introducing microbiome-friendly products that are presented as natural, science-proven remedies for staying healthy. This is also being supported by the growing demand for personalized nutrition, where diet regimes and supplements are formulated based on an individual's microbiome profile. Social media, health campaigns, and science communication are disseminating information regarding the function of the microbiome, thus making changes to consumer behavior. Consumer retail channels and e-commerce platforms also increase accessibility to products that are microbiome-related, driving demand. Since health-aware consumers increasingly favor preventive care and natural remedies over drug therapy, the functional foods and supplements industry is constantly enhancing its influence on market development. In 2024, dsm-firmenich, leaders in nutrition, health and beauty, and Lallemand Health Solutions, experts in probiotics, revealed a revolutionary collaboration to introduce novel synergistic synbiotic offerings for early life nutrition. The innovative solutions merged human milk oligosaccharides (HMOs) from dsm-firmenich with probiotics from Lallemand Health Solutions to deliver possible synergistic advantages that promote infant health and growth. These solutions target fostering a microbiome similar to that of breast-fed infants and advancing the immune system, the gut microbiome, and ideal developmental pathways.

Human Microbiome Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global human microbiome market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on product, application, and disease type.

Analysis by Product:

  • Probiotics
  • Prebiotics
  • Diagnostic Tests
  • Drugs
  • Medical Food
  • Others

Probiotics stand as the largest component in 2025, holding 43.2% of the market. Probiotics are providing major health advantages by maintaining the balance of healthy bacteria in the human gut. Live microorganisms are enhancing digestive wellness by promoting nutrient uptake, modulating bowel function, and lowering the risk of gastrointestinal illness like diarrhea, constipation, and irritable bowel syndrome. Through a balanced gut microbiome, probiotics are enhancing the body's own defense systems against disease-causing pathogens. Along with supportive digestive function, probiotics are boosting immune system function. They are activating antibody production and affecting immune cell function, and this is assisting the body in responding better to infection. Probiotics are also aiding metabolic health through aiding in weight management and enhancing insulin sensitivity, thus lowering risks associated with obesity and type 2 diabetes. Rising research is emphasizing their contribution to mental health, with gut microbiota affecting brain function via the gut-brain axis. This link is displaying promising implications for the reduction of stress, mood modulation, and cognitive function.

Analysis by Application:

  • Therapeutics
  • Diagnostics

Therapeutics lead the market with 82.1% of market share in 2025. They are yielding significant benefits by treating a broad array of medical ailments with tailored interventions. They are enhancing patient outcomes through treating chronic conditions, infectious diseases, and metabolic disorders using evidence-based modalities. Advanced therapeutics are moving beyond traditional medicines, as biologics, cell therapies, and microbiome therapies provide more targeted and personalized treatments. This transition is minimizing side effects while increasing treatment efficacy, as therapies become more addressed to the unique patient profile. Beyond disease treatment, therapeutics are stepping into preventive medicine as well. They are assisting in the early treatment of diseases like cardiovascular disease, diabetes, and cancer, thus reducing long-term medical expenses and enhancing the quality of life. Numerous therapeutics are also improving mental well-being by addressing neurological and psychiatric disorders so that they facilitate enhanced emotional and cognitive stability. Through ongoing improvements in biotechnology and genomics, therapeutics are providing safer, more efficacious, and highly individualized treatments.

Analysis by Disease Type:

  • Obesity
  • Diabetes
  • Autoimmune Disorders
  • Cancer
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Others

Obesity leads the market with 26.9% of market share in 2025. Obesity, as a disease, is becoming a prominent area of focus in healthcare research because of its growing prevalence globally. Obesity is being realized as a multifactorial, chronic condition with etiologic factors related to genetics, behavior, environment, and metabolism. The ailment is linked to excess accumulation of fat that is compromising overall well-being and strongly increasing the risk of cardiovascular diseases, type 2 diabetes, hypertension, and some cancers. The increased prevalence of obesity is exacting a high economic and clinical cost on healthcare systems, leading to increased interest in preventive and curative approaches. Obesity has been studied as a focus area in the human microbiome market due to the influence of the microbiome on metabolism, energy balance, and fat storage. The work is revealing that disruptions in gut microbiota are adding to weight increase and metabolic disease. This awareness is propelling the formulation of microbiome-derived therapeutics, customized nutrition, and probiotics that can help better control and prevent obesity.

Regional Analysis:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of 43.5%. The human microbiome sector in North America is experiencing growth as research institutions, biotechnology firms, and pharmaceutical companies are investing heavily in microbiome-focused innovations. The region is witnessing rising demand for microbiome-based therapeutics that are targeting gastrointestinal disorders, metabolic diseases, autoimmune conditions, and cancer. Companies are continuously developing advanced probiotics, prebiotics, and functional foods that are supporting digestive and immune health, while personalized nutrition solutions are gaining momentum as consumers are seeking individualized approaches to wellness. Technological advancements in next-generation sequencing and bioinformatics are enabling deeper analysis of microbial ecosystems, which is supporting clinical research and accelerating drug discovery. Funding from government agencies, venture capital firms, and private investors is increasing, allowing start-ups and established players to expand their pipelines and bring innovative products to market.

Key Regional Takeaways:

United States Human Microbiome Market Analysis

The United States holds 88.90% share in North America. The country is witnessing increased human microbiome adoption driven by the escalating burden of chronic lifestyle diseases. For instance, 6 out of 10 Americans have one chronic disease and four out of 10 have two or more chronic diseases that account for ninety percent of the USD 4.5 Trillion annual health care costs in the nation. The rising incidence of conditions such as cardiovascular disorders, metabolic syndrome, and inflammatory bowel diseases has spurred interest in personalized microbiome-based interventions. Healthcare systems are exploring microbiome-targeted therapies to manage and mitigate long-term complications associated with these chronic ailments. Pharmaceutical and biotech firms are investing in R&D focused on the gut-brain axis and gut-immune system. Additionally, patients are becoming more aware of microbiome diagnostics and probiotics as complementary strategies to traditional medicine. Growing public and private funding is reinforcing innovation in the microbiome segment.

Asia Pacific Human Microbiome Market Analysis

Asia-Pacific is experiencing accelerated human microbiome adoption influenced by the sharp increase in diabetes cases across the region. For instance, in 2025, diabetes had become a crucial health issue in India, with around 101 Million people currently diagnosed and 136 Million more estimated to be pre-diabetic. Rising sedentary lifestyles, dietary changes, and genetic predispositions have contributed to a growing diabetic population, prompting demand for innovative approaches to glucose regulation and metabolic health. Microbiome-based diagnostics and therapeutic solutions are gaining traction as they help identify gut flora imbalances linked to insulin resistance and type 2 diabetes. Research institutions and biotech companies are emphasizing microbiome modulation to prevent disease progression. As awareness about gut microbiota's role in metabolic health expands, preventive care programs and personalized nutrition plans incorporating microbiome data are gaining popularity.

Europe Human Microbiome Market Analysis

Europe is seeing a growing human microbiome adoption trend due to its increasing geriatric population. According to the WHO, the population aged 60 and older is rapidly growing in the WHO European Region. In 2021, there were 215 Million; by 2030, it is projected to be 247 Million, and by 2050, over 300 Million. As the elderly demographic expands, age-related health concerns such as weakened immunity, gastrointestinal issues, and neurodegenerative diseases are becoming more prevalent. Microbiome-focused healthcare solutions are being explored to improve longevity, manage inflammation, and enhance cognitive and digestive function. Researchers are developing microbiota-based therapies to support healthy aging, while nutraceutical companies are offering customized probiotics targeting age-specific concerns. Health institutions across the region are also integrating microbiome testing in geriatric care protocols.

Latin America Human Microbiome Market Analysis

Latin America is witnessing increased human microbiome interest as obesity cases continue to rise significantly. For instance, in LA about 64% of adults are overweight, from which 30.5% are obese, with numbers on the rise and affecting the entire population from early childhood. The prevalence of poor dietary habits and reduced physical activity is driving metabolic disorders across various age groups. Microbiome-based interventions are being studied for their ability to modulate gut flora, reduce inflammation, and assist in weight management.

Middle East and Africa Human Microbiome Market Analysis

Middle East and Africa are adopting human microbiome solutions at a growing pace due to the increasing cancer cases observed across the region. For instance, Saudi Arabia reported 27% of the GCC's total cancer cases, with an estimated 18,000 new diagnoses annually. With cancer treatments often impacting gut health and immunity, microbiome-targeted therapies are being incorporated into supportive care regimens. Researchers and healthcare providers are exploring how gut microbiota modulation can enhance treatment outcomes, reduce side effects, and improve recovery.

Competitive Landscape:

Market players in the human microbiome industry are actively engaging in research collaborations, product innovation, and strategic partnerships to strengthen their market presence. Companies are investing in advanced sequencing technologies and bioinformatics platforms to accelerate drug discovery and develop microbiome-based therapeutics targeting gastrointestinal, metabolic, and autoimmune disorders. Food and supplement manufacturers are launching probiotics, prebiotics, and functional foods that are catering to rising consumer demand for gut health and preventive care. Partnerships between pharmaceutical firms, biotech start-ups, and academic institutions are fostering innovation and clinical validation. Additionally, as per human microbiome market forecasts, market players are expected to secure funding from investors and government agencies, expanding clinical pipelines, and focusing on personalized nutrition and precision medicine to capture growing opportunities.

The report provides a comprehensive analysis of the competitive landscape in the human microbiome market with detailed profiles of all major companies, including:

  • 4D pharma plc
  • Atlas Biomed Group Limited
  • BIOHM
  • BiomX, Bione
  • DayTwo Inc.
  • ENTEROME
  • Ferring B.V.
  • Finch Therapeutics
  • Second Genome Inc.
  • SynBioBeta LLC
  • Synthetic Biologics Inc.
  • Vedanta Biosciences Inc.
  • Viome Inc.

Key Questions Answered in This Report

  • 1.How big is the human microbiome market?
  • 2.What is the future outlook of human microbiome market?
  • 3.What are the key factors driving the human microbiome market?
  • 4.Which region accounts for the largest human microbiome market share?
  • 5.Which are the leading companies in the global human microbiome market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Microbiome Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Probiotics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Prebiotics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Diagnostic Tests
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Drugs
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Medical Food
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Therapeutics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diagnostics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Disease Type

  • 8.1 Obesity
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diabetes
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoimmune Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Gastrointestinal Disorders
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Central Nervous System Disorders
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 4D pharma plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Atlas Biomed Group Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 BIOHM
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 BiomX
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bione
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 DayTwo Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 ENTEROME
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Ferring B.V.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Finch Therapeutics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Second Genome Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 SynBioBeta LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Synthetic Biologics Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Vedanta Biosciences Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
    • 14.3.14 Viome Inc.
      • 14.3.14.1 Company Overview
      • 14.3.14.2 Product Portfolio

List of Figures

  • Figure 1: Global: Human Microbiome Market: Major Drivers and Challenges
  • Figure 2: Global: Human Microbiome Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Human Microbiome Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Human Microbiome Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Human Microbiome Market: Breakup by Disease Type (in %), 2025
  • Figure 7: Global: Human Microbiome Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Human Microbiome (Probiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Human Microbiome (Probiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Human Microbiome (Prebiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Human Microbiome (Prebiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Human Microbiome (Diagnostic Tests) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Human Microbiome (Diagnostic Tests) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Human Microbiome (Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Human Microbiome (Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Human Microbiome (Medical Food) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Human Microbiome (Medical Food) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Human Microbiome (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Human Microbiome (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Human Microbiome (Therapeutics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Human Microbiome (Therapeutics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Human Microbiome (Diagnostics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Human Microbiome (Diagnostics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Human Microbiome (Obesity) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Human Microbiome (Obesity) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Human Microbiome (Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Human Microbiome (Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Human Microbiome (Autoimmune Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Human Microbiome (Autoimmune Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Human Microbiome (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Human Microbiome (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Human Microbiome (Gastrointestinal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Human Microbiome (Gastrointestinal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Human Microbiome (Central Nervous System Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Human Microbiome (Central Nervous System Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Human Microbiome (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Human Microbiome (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: North America: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: North America: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: United States: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: United States: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Canada: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Canada: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Asia-Pacific: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Asia-Pacific: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: China: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: China: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Japan: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Japan: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: India: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: India: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: South Korea: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: South Korea: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Australia: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Australia: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Indonesia: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Indonesia: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Others: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Others: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Europe: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Europe: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Germany: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Germany: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: France: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: France: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: United Kingdom: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: United Kingdom: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Italy: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Italy: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Spain: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Spain: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Russia: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Russia: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Latin America: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Latin America: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Brazil: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Brazil: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Mexico: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Mexico: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Others: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Others: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Middle East and Africa: Human Microbiome Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Middle East and Africa: Human Microbiome Market: Breakup by Country (in %), 2025
  • Figure 86: Middle East and Africa: Human Microbiome Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Global: Human Microbiome Industry: SWOT Analysis
  • Figure 88: Global: Human Microbiome Industry: Value Chain Analysis
  • Figure 89: Global: Human Microbiome Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Microbiome Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Human Microbiome Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Human Microbiome Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Human Microbiome Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 5: Global: Human Microbiome Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Human Microbiome Market: Competitive Structure
  • Table 7: Global: Human Microbiome Market: Key Players